Cynata Therapeutics |
Market Cap (3-Oct) $2,677,998 (1,053rd) |
Close (30-Jun) $0.125 |
Volume (30-Jun) 400,697 |
Shortsold (13-May) 3,127 (0.00%) (661st) |
|
52w High $0.435 |
52w Low $0.010 |
P/E - |
EPS -0.04 |
[ARTICLE] Why this CEO brainstorms while sitting on a surfboard
A news article has been posted about Cynata Therapeutics on the AFR. The article was published around , on 11 July 2022 at 9:14am.
Cynata Therapeutics boss Dr Ross Macdonald likes to think outside the box when solving problems. Where better to do so than off the coast?
Read ArticleCYP was $0.37 at the close of trade on 08 July 2022
| Recent Articles about ASX:CYP | |
|---|---|
| 1-Oct | Notification of cessation of securities - CYP - 11 Sep 2026
company-announcements.afr.com |
| 28-Sep | CYP:ASX Announcement - Appendix 4G - 28 Sep 2026
company-announcements.afr.com |
| 29-Aug | Actinogen Appendix 4E and 2026 digital annual report - AFR
company-announcements.afr.com |
| 26-Aug | Acrux Ltd (ACR:ASX) - AFR
company-announcements.afr.com |
| 25-Aug | Acrux Ltd (ACR:ASX) - AFR
company-announcements.afr.com |
| 3-Aug | CYP:ASX Announcement - Expected Timing of Clinical Trial Results
company-announcements.afr.com |
| 4-Jul | Form 603 - Corporations Act 2001 Section 671B - AFR
company-announcements.afr.com |
| 3-Jul | Form 605 Notice of ceasing to be a substantial holder - AFR
company-announcements.afr.com |
| 3-Jul | CYP-001 Graft Versus Host Disease Trial: Primary Evaluation Results
company-announcements.afr.com |
| 3-Jul | Market Announcement - Moomoo
company-announcements.afr.com |
| Tracked |
Find all articles about Cynata Therapeutics, including others on the AFR, on the media page.
You must be logged in to post a reply.